drugset / Trial / NCT04799431
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Phase 1
Withdrawn
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).
Timeline
- Start
- 2023-05-03
- Primary completion
- 2023-05-03
- Completion
- 2023-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NeoVax | Vaccine | 0.3 mg | Subcutaneous |
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |
| Background | Hiltonol | Other / unclassified | 0.5 mg | Subcutaneous |